Valuation : United Therapeutics Corporation

Market Cap 21.36B 18.36B 17.28B 15.77B 29.42B 2,025B 29.57B 205B 79.2B 1,035B 80.2B 78.45B 3,293B P/E 2026 *
19.1x
P/E 2027 * 17.4x
Enterprise Value 18.39B 15.81B 14.87B 13.57B 25.33B 1,743B 25.46B 176B 68.17B 891B 69.04B 67.53B 2,835B EV / Sales 2026 *
5.86x
EV / Sales 2027 * 5.1x
Free-Float
53.72%
Yield 2026 *
-
Yield 2027 * -
1 day+0.37%
1 week+1.91%
Current month-1.75%
1 month-5.33%
3 months-9.35%
6 months-5.24%
Current year+2.91%
1 week 477.06
Extreme 477.06
505
1 month 477.01
Extreme 477.01
540.56
Current year 455.63
Extreme 455.63
609.35
1 year 395
Extreme 395
609.35
3 years 208.62
Extreme 208.6249
609.35
5 years 158.38
Extreme 158.38
609.35
10 years 74.31
Extreme 74.31
609.35
Manager TitleAgeSince
Chief Executive Officer 71 26/06/1996
President 54 26/06/2016
Director of Finance/CFO 58 13/03/2015
Director TitleAgeSince
Director/Board Member 78 01/01/2002
Chairman 71 26/06/1996
Director/Board Member 92 01/01/2002
Date Insider Type Main position Quantity % Market Cap. Importance
9/3/26 A Exercice

Chief Executive Officer

28,500 0.0671%
9/3/26 A Exercice

General Counsel

24,900 0.0587%
9/2/26 A Exercice

Chief Executive Officer

28,500 0.0671%
Change 5-day change 1-year change 3-year change Capi.($)
+0.40%+1.91%+24.18%+122.55% 21.36B
+0.34%-2.75%+50.30%+89.43% 1,002B
-0.13%-2.45%+51.71%+65.04% 649B
+0.34%-4.56%+18.71%+67.59% 440B
-0.76%-0.37%+29.00%+37.02% 346B
-0.09%-14.97%+9.41%+26.44% 263B
-1.80%-2.59%-2.59%+11.08% 250B
-0.06%-11.26%+40.37%+50.15% 213B
-1.06%-4.23%-14.70%-57.76% 201B
-0.15%-2.36%+26.19%+89.61% 182B
Average -0.31%-2.14%+23.25%+50.12% 356.5B
Weighted average by Cap. -0.17%-2.39%+32.23%+56.66%

Financials

2026 *2027 *
Net sales 3.14B 2.7B 2.54B 2.32B 4.32B 298B 4.35B 30.09B 11.64B 152B 11.79B 11.53B 484B 3.44B 2.96B 2.78B 2.54B 4.74B 326B 4.77B 32.99B 12.76B 167B 12.92B 12.64B 531B
Net income 1.2B 1.03B 969M 884M 1.65B 114B 1.66B 11.48B 4.44B 58.02B 4.5B 4.4B 185B 1.32B 1.13B 1.07B 973M 1.82B 125B 1.82B 12.63B 4.89B 63.85B 4.95B 4.84B 203B
Net Debt -2.97B -2.56B -2.4B -2.19B -4.09B -282B -4.12B -28.49B -11.02B -144B -11.16B -10.92B -458B -3.81B -3.27B -3.08B -2.81B -5.24B -361B -5.27B -36.48B -14.11B -184B -14.29B -13.98B -587B
Logo United Therapeutics Corporation
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions. It markets and sells commercial products, including Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI), Tyvaso (treprostinil) Inhalation Solution (Nebulized Tyvaso), Remodulin (treprostinil) Injection (Remodulin), Orenitram (treprostinil) Extended-Release Tablets (Orenitram), Unituxin (dinutuximab) Injection (Unituxin) and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and Nebulized Tyvaso to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). Unituxin, an infused monoclonal antibody for the treatment of high-risk neuroblastoma and for the treatment of neuroblastoma after high-dose chemotherapy. Adcirca, an oral immediate-release tablet form of the PDE-5 inhibitor tadalafil. Its THY-100 is in preclinical development for congenital athymia.
Employees
1,400
Date Price Change Volume
09/09/26 $500.99 +0.61% 95,967
08/09/26 $497.97 +2.12% 643,543
04/09/26 $487.61 -0.54% 327,024
03/09/26 $490.24 -0.36% 469,576
02/09/26 $492.02 -4.03% 1,404,131
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
497.97USD
Average target price
664.33USD
Spread / Average Target
+33.41%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. UTHR Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!